Emerging evidence suggests that BRCA1 pathway contributes to the behavior of sporadic triple negative breast cancer (TNBC), but little is known about the mechanisms underlying this association. Considering the central role that microRNAs (miRNAs) play in gene expression regulation, the aim of this study was to identify miRNAs specifically deregulated in TNBC and investigate their involvement in...

Breast cancer is the most common malignancy in women and the leading cause of cancer mortality worldwide. Triple-negative breast cancer (TNBC) is an important phenotype of breast cancer that accounts for a relatively small number of breast cancer cases but still represent a focus of increasing interest at the clinical, biological, and epidemiological level. Claudins are the major component of t...

PURPOSE Triple-negative breast cancer (TNBC) has attracted more attention both clinically and experimentally because of its high-risk biological characteristics and lacking of effective treatment method. The purpose of this retrospective study was to find out the incidence of triple-negative breast cancer (TNBC) in all kinds of breast cancers and to compare and analyze the clinicopathological f...

Tumor heterogeneity of triple-negative breast cancer (TNBC) has been the main barrier in conquering breast cancer. To dissect the molecular diversity of TNBC and discover therapeutic targets for TNBC, the molecular classification of TNBC is a prioritized issue in research area. Accordingly, recent studies have been successful in classifying TNBC into several distinct subtypes with specific biol...

PURPOSE Although most patients with stage I breast cancer have a good prognosis, their clinical outcomes may vary significantly. We assessed clinical outcomes and prognostic factors in stage I breast cancer patients with and without triple-negative breast cancer (TNBC) phenotype. METHODS Of 2,489 patients undergoing breast cancer surgery between January 1998 and December 2002, 554 (22.3%) had...

background: because of the reported poor prognosis and absence of effective and specific therapeutic approaches, triple-negative breast cancer (tnbc) tumors have remained as an important area of investigations for clinicians and researchers. the aim of this study was to determine the clinical, pathological, histological, prognostic features, and outcome associated with this type of breast cance...

Triple-negative breast cancer (TNBC) is considered a rare diagnosis. This malignancy targets a specific population of women and has risk factors differing from those of other breast cancers. TNBC exhibits distinct pathologic features that result in aggressive metastasis and poor prognosis. Pathologically, TNBC cancer cells are characterized by negative receptors for progesterone and estrogen an...

The most aggressive subtype of Breast Cancer (BC) is Triple Negative Breast Cancer (TNBC) that accounting for 10-22% of all breast cancer patients [1,2]. The most deadly factors of TNBC are early relapse and distant metastases, especially brain metastases, currently lacking of effective treatment targets [3,4]. Here, we report a rare case of TNBC patient with metastasis to opposite chest organs...

Approximately 15% of breast cancers lack expression of oestrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2).1 This triple-negative breast cancer (TNBC) is an aggressive disease: About 30% of patients will develop metastatic disease, whereby symptomatic visceral and brain metastases are common and the median survival is approximately 13 months...

Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases. TNBC is an immunohistochemically defined subtype, with significant diversity within the subtype. Generally TNBC occurs in younger women and is marked by high rates of relapse, visceral and CNS metastases, and early death. Current therapy fails to curtail the innate aggressive behaviour of TNBC in the maj...